item management s discussion and analysis of financial condition and results of operations results of operations all share and per share data included in management s discussion and analysis of financial condition and results of operations have been adjusted for the june and june two for one stock splits 
the following table presents sales and results of operations for omnicare  inc the company  excluding pooling of interests expenses in thousands  except per share amounts for the years ended december  sales    net income  as reported    acquisition expenses  pooling of interests net of taxes  pro forma net income    pro forma earnings per share net income  as reported 


acquisition expenses  pooling of interests net of taxes 


primary 


fully diluted 


vs 
excluding the impact of charges taken for acquisitions accounted for as pooling of interests transactions  pro forma net income for the year ended december  increased over net income earned in primary earnings per share  on this basis  for increased over  and fully diluted earnings per share increased 
sales increased in versus the sales increase was the result of the completion of institutional pharmacy acquisitions in see note of the consolidated financial statements and internal growth 
internal growth resulted from an increase in acuity levels of residents in client facilities  expansion of services such as infusion therapy and drug price inflation  as well as the addition of new clients through the efforts of the company s national sales and marketing group and pharmacy staff 
acquisitions and internal growth brought the total number of nursing facility residents served at december  to  up from the prior year end 
gross margin improvements from in to in resulted from changes in sales mix  including increased infusion therapy revenue  and the company s increased leverage in purchasing and fixed overhead costs 
excluding the aforementioned pro forma adjustments for pooling of interests expenses  operating income as a percent of sales increased from in to in  reflecting the gross margin improvement 
investment income increased by to  in as the company realized the benefit of investing the net proceeds of million from the march stock offering for the majority of the year 
interest expense decreased from  in to  in  primarily due to the conversion of the convertible subordinated notes during the effective tax rates of in and in are marginally higher than statutory rates due primarily to the nondeductibility of certain acquisition costs 
vs 
sales increased in versus the sales increase was the result of nine institutional pharmacy acquisitions in see note of the consolidated financial statements and internal growth 
internal growth resulted from the higher acuity levels of residents in client facilities  expansion of services such as infusion therapy  drug price inflation and the addition of new clients owing to the efforts of the company s national sales and marketing group  initiated late in  and the pharmacy staff 
acquisitions and internal growth brought the total number of nursing facility residents served at december  to  up from the prior year end 
gross margin improvements from in to in resulted from changes in sales mix  including increased infusion therapy revenue  and the company s increased leverage in purchasing and fixed overhead costs 
excluding the aforementioned pro forma adjustments for pooling of interests expenses  operating income as a percent of sales increased from in to in  primarily reflecting the gross margin improvement 
investment income increased by to  in as the company realized the benefit of invested cash during due to receipt of million of net proceeds from the november stock offering 
interest expense decreased from  in to  in  primarily due to reductions in outstanding debt associated with specialized pharmacy services  inc specialized and evergreen pharmaceutical  inc 
evergreen prior to acquisition by the company  these acquisitions were accounted for as poolings of interests  and accordingly  specialized and evergreen are included in the company s financial results for all years presented 
the company s effective tax rates decreased from in to in the effective tax rates are marginally higher than statutory rates due primarily to the nondeductibility of certain acquisition costs 
impact of inflation inflation has not materially affected omnicare s profitability inasmuch as price increases have generally been obtained to cover inflationary drug cost increases 
liquidity and capital resources acquisitions completed during utilized cash of million and deferred cash payments of million were made relating to pre acquisitions 
such acquisitions were also financed  in part  with common stock of the company 
shares of common stock with a market value of approximately million  shares were issued in connection with acquisitions and  shares with a market value of  were issued in in connection with pre acquisitions 
additional amounts totaling million may become payable through the year pursuant to the terms of various acquisition agreements 
on october   the company issued  principal amount of convertible subordinated notes notes due the notes were convertible into common stock at any time at the option of the holder at a price of per share 
the remaining notes were converted in october into  shares of common stock 
prior to the october conversion  notes were converted into  shares of common stock during in october  the company entered into an agreement with a consortium of sixteen banks for a million revolving credit facility  replacing the prior million facility 
interest rates and commitment fees for this new facility are based on the company s level of performance under certain debt covenants 
no amounts were outstanding at december  under the credit facility 
at december   the company had invested  in us treasury backed repurchase agreements 
these securities are usually held overnight  but in no case are they held longer than days  under agreements to resell the securities to the counterparty 
the company has a collateralized interest in the underlying securities which are segregated in the accounts of the counterparty bank 
omnicare s current ratio increased to to at december  from to at december   and working capital at december  increased to  from year end working capital of  this increase is primarily attributable to the cash proceeds received relating to the company s march stock offering of  shares pre stock split of common stock  resulting in net proceeds of million 
book value per common share increased to per share as of december  from per share at the prior year end  primarily attributable to the current year stock offering and net income  partially offset by dividends paid 
on february   omnicare s board of directors elected to increase the quarterly cash dividend by to cents per share for an indicated annual rate of cents per share for the company believes that its sources of liquidity and capital are adequate for its operating needs 
there are no material commitments and contingencies outstanding  other than additional acquisition related payments to be made see note of the consolidated financial statements 
if needed  other external sources of financing are readily available to the company 
outlook as in the past several years  federal policy makers continue to propose various plans to contain or reduce health care costs 
while it is not possible to predict the future of any such proposals  market forces nevertheless continue to challenge health care providers to lower costs while maintaining or improving quality 
in this environment  the need to lower health care costs will drive ongoing industry consolidation  which should continue to provide momentum for the company s acquisition program 
moreover  the development of the company s institutional pharmacy network in key geographic regions provides opportunities for economies of scale to lower overall costs 
in addition  omnicare s proprietary geriatric formulary not only lowers costs for payors and patients  but also enhances the quality of care for the elderly 
demographic trends also indicate that demand for long term care will increase well into the middle of the next century as the elderly population grows significantly 
pharmaceutical therapy is generally considered the most cost effective form of treatment for chronic ailments afflicting the elderly and  as such  is an essential part of long term care 
omnicare believes it is well positioned to meet the challenges of today s health environment through a number of initiatives  including drug formulary management  cost effective drug purchasing and efficient delivery systems 
additionally  omnicare s pharmacy consulting services for nursing facilities identify  resolve and prevent drug therapy related problems  reducing costs to the health care system while also promoting optimal patient outcomes 
omnicare also recently agreed to acquire a contract research organization  which should provide additional opportunities to leverage the company s geriatric pharmaceutical expertise 
management believes omnicare is strategically positioned for continued sales and earnings growth in safe harbor statement under the private securities litigation reform act of regarding forward looking information in addition to historical information  this report contains forward looking statements and performance trends which are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements and trends 
such factors include  but are not limited to the continued availability of suitable acquisition candidates  changing economic and market conditions that could impact the suitability of such candidates  omnicare s ability to integrate acquisitions  the effect of changes in government regulation and reimbursement policies and in the interpretation and application of such policies  and the failure of the company to obtain or maintain required regulatory approvals or licenses 
see the competition  government regulation and legal proceedings sections at item of this report 

